Skip to main content
NASDAQ:SGEN

Seagen Stock Forecast, Price & News

$148.23
+0.25 (+0.17 %)
(As of 05/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$146.95
$152.36
50-Day Range
$135.08
$149.64
52-Week Range
$133.20
$213.94
Volume994,455 shs
Average Volume1.11 million shs
Market Capitalization$26.90 billion
P/E Ratio58.36
Dividend YieldN/A
Beta1.11
30 days | 90 days | 365 days | Advanced Chart
Receive SGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter.


Seagen logo

About Seagen

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; and Merck. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SGEN
CUSIP81257810
Phone425-527-4000
Employees2,092
Year Founded1998

Sales & Book Value

Annual Sales$916.71 million
Book Value$10.95 per share

Profitability

Net Income$-158,650,000.00

Debt

Price-To-Earnings

Miscellaneous

Market Cap$26.90 billion
Next Earnings Date7/29/2021 (Estimated)
OptionableOptionable

Social Links


MarketRank

Overall MarketRank

1.50 out of 5 stars

Medical Sector

560th out of 2,050 stocks

Biological Products, Except Diagnostic Industry

77th out of 177 stocks

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Seagen (NASDAQ:SGEN) Frequently Asked Questions

Is Seagen a buy right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 6 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Seagen stock.
View analyst ratings for Seagen
or view top-rated stocks.

What stocks does MarketBeat like better than Seagen?

Wall Street analysts have given Seagen a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Seagen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Seagen's next earnings date?

Seagen is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Seagen
.

How were Seagen's earnings last quarter?

Seagen Inc. (NASDAQ:SGEN) announced its earnings results on Thursday, April, 29th. The biotechnology company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.59) by $0.08. The biotechnology company earned $331.98 million during the quarter, compared to analyst estimates of $341.39 million. Seagen had a trailing twelve-month return on equity of 20.46% and a net margin of 25.34%.
View Seagen's earnings history
.

How has Seagen's stock been impacted by Coronavirus (COVID-19)?

Seagen's stock was trading at $104.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SGEN stock has increased by 41.8% and is now trading at $148.23.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for SGEN?

16 brokerages have issued 12 month target prices for Seagen's shares. Their forecasts range from $145.00 to $254.00. On average, they anticipate Seagen's stock price to reach $186.36 in the next twelve months. This suggests a possible upside of 25.7% from the stock's current price.
View analysts' price targets for Seagen
or view top-rated stocks among Wall Street analysts.

Who are Seagen's key executives?

Seagen's management team includes the following people:
  • Dr. Clay B. Siegall, Co-Founder, Chairman, Pres & CEO (Age 60, Pay $2.64M) (LinkedIn Profile)
  • Mr. Todd E. Simpson, Chief Financial Officer (Age 60, Pay $620.67k)
  • Ms. Jean I. Liu, Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec. (Age 53, Pay $963.45k) (LinkedIn Profile)
  • Mr. Charles R. Romp, Exec. VP of Commercial U.S. (Age 53, Pay $829.16k) (LinkedIn Profile)
  • Dr. Roger D. Dansey M.D., Chief Medical Officer (Age 64, Pay $1.65M) (LinkedIn Profile)
  • Dr. Vaughn B. Himes, Chief Technical Officer (Age 60) (LinkedIn Profile)
  • Peggy Pinkston, VP of Investor Relations
  • Ms. Nancy Whiting B.Sc., Pharm.D., Exec. VP of Corp. Strategy, Alliances & Communications (LinkedIn Profile)
  • Ms. Natasha A. Hernday, Exec. VP of Corp. Devel. (Age 49) (LinkedIn Profile)
  • Mr. Matt Skelton, VP of Marketing

What is Clay B. Siegall's approval rating as Seagen's CEO?

107 employees have rated Seagen CEO Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among Seagen's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Seagen's key competitors?

What other stocks do shareholders of Seagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), salesforce.com (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

What is Seagen's stock symbol?

Seagen trades on the NASDAQ under the ticker symbol "SGEN."

Who are Seagen's major shareholders?

Seagen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Capital International Investors (8.62%), BlackRock Inc. (6.93%), Price T Rowe Associates Inc. MD (3.92%), Primecap Management Co. CA (2.76%), JPMorgan Chase & Co. (2.66%) and Nuveen Asset Management LLC (0.93%). Company insiders that own Seagen stock include Bros Advisors Lp Baker, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, David W Gryska, Jean I Liu, Lip Bu Tan, Marc E Lippman, Roger D Dansey, Srinivas Akkaraju, Todd E Simpson and Vaughn B Himes.
View institutional ownership trends for Seagen
.

Which institutional investors are selling Seagen stock?

SGEN stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Massachusetts Financial Services Co. MA, JPMorgan Chase & Co., Putnam Investments LLC, Price T Rowe Associates Inc. MD, Primecap Management Co. CA, Lord Abbett & CO. LLC, and Jennison Associates LLC. Company insiders that have sold Seagen company stock in the last year include Charles R Romp, Clay B Siegall, Daniel G Welch, David W Gryska, Jean I Liu, Roger D Dansey, Todd E Simpson, and Vaughn B Himes.
View insider buying and selling activity for Seagen
or view top insider-selling stocks.

Which institutional investors are buying Seagen stock?

SGEN stock was bought by a variety of institutional investors in the last quarter, including Redmile Group LLC, Manning & Napier Group LLC, Point72 Asset Management L.P., UBS Asset Management Americas Inc., Renaissance Technologies LLC, Voloridge Investment Management LLC, Mirae Asset Global Investments Co. Ltd., and Franklin Resources Inc..
View insider buying and selling activity for Seagen
or or view top insider-buying stocks.

How do I buy shares of Seagen?

Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seagen's stock price today?

One share of SGEN stock can currently be purchased for approximately $148.23.

How much money does Seagen make?

Seagen has a market capitalization of $26.90 billion and generates $916.71 million in revenue each year. The biotechnology company earns $-158,650,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis.

How many employees does Seagen have?

Seagen employs 2,092 workers across the globe.

Does Seagen have any subsidiaries?

The following companies are subsidiares of Seagen: Cascadian Therapeutics.

When was Seagen founded?

Seagen was founded in 1998.

What is Seagen's official website?

The official website for Seagen is www.seattlegenetics.com.

Where are Seagen's headquarters?

Seagen is headquartered at 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021.

How can I contact Seagen?

Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at 425-527-4000 or via email at [email protected]


This page was last updated on 5/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.